Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

Table 2 Patient-reported outcome scores at baseline (intention-to-treat population)

Patient-reported outcome	Sarilumab SC 200 mg q2w (n = 184)	Adalimumab SC 40 mg q2w (n = 185)
HAQ-DI^a	1.6 (0.55)	1.6 (0.64)
Pain VAS^b	71.6 (18.65)	71.4 (18.96)
PtGA^b	68.0 (17.49)	67.8 (18.41)
SF-36^c
PCS	30.7 (6.15)	31.4 (6.59)
MCS	36.7 (10.67)	37.1 (11.83)
Physical functioning	33.3 (20.04)	35.7 (21.73)
Role physical	34.4 (18.88)	34.2 (20.08)
Bodily pain	26.7 (14.75)	28.4 (16.55)
General health	34.4 (15.64)	36.1 (16.21)
Vitality	33.4 (16.42)	35.5 (17.87)
Social functioning	46.5 (23.23)	47.4 (26.03)
Role emotional	47.1 (24.44)	47.4 (27.25)
Mental health	49.0 (18.52)	50.5 (19.69)
FACIT-F^d	23.6 (9.01)	24.0 (10.31)
Morning stiffness VAS^b	70.8 (18.99)	68.0 (21.37)
RAID score (0–10)^e	6.7 (1.72)	6.4 (2.03)
WPS-RA
Employed outside the home, n (%)	78 (42.6)	69 (37.5)
Work days missed	2.5 (5.26)	2.0 (5.11)
Days with work productivity reduced by ≥ 50%	5.8 (7.03)	4.9 (7.66)
Interference with work productivity^f	5.6 (2.62)	4.8 (2.98)
Housework days missed	8.7 (8.14)	7.3 (9.06)
Days with household productivity reduced by ≥ 50%	10.0 (8.78)	9.4 (9.68)
Interference with household productivity	6.5 (2.60)	6.3 (2.88)
Days with family, social, or leisure activities missed	5.4 (7.84)	5.6 (8.51)
Days with outside help hired	5.2 (8.43)	4.6 (8.57)

Abbreviations: FACIT-F Functional Assessment of Chronic Illness Therapy–Fatigue; HAQ-DI Health Assessment Questionnaire Disability Index, MCS Mental Component Summary, PCS Physical Component Summary, PtGA Patient global assessment of disease activity, q2w Every 2 weeks, RAID Rheumatoid Arthritis Impact of Disease, SC Subcutaneous, SF-36 36-item Short Form Health Survey, VAS Visual analogue scale, WPS-RA Rheumatoid arthritis-specific Work Productivity Survey
^aScale range, 0–3; lower scores represent less difficulty with physical functioning
^bScale range, 0–100; lower scores indicate better outcomes
^cScale range, 0–100; higher scores represent less impaired physical/mental health status
^dScale range, 0–52; higher scores represent less fatigue
^eScale range, 0–10; higher scores indicate a greater (negative) impact of RA
^fScale range, 0 = no interference to 10 = complete interference

ISSN: 1478-6362